Compare SRTAW & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SRTAW | ERNAW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 601 | 5 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2019 | N/A |
| Metric | SRTAW | ERNAW |
|---|---|---|
| Price | $0.00 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 82.7K | 81.3K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.00 | $0.02 |
| 52 Week High | $0.29 | $0.23 |
| Indicator | SRTAW | ERNAW |
|---|---|---|
| Relative Strength Index (RSI) | 34.91 | 56.09 |
| Support Level | N/A | $0.04 |
| Resistance Level | $0.19 | $0.23 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 1.56 | 54.55 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.